The American Association for Cancer Research (AACR) is a scientific society consisting of over 13,500 laboratory and clinical cancer researchers. It was founded in 1907 "to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world." Members of the AACR enjoy the following benefits:

- the opportunity to subscribe to AACR's four prestigious journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention, at reduced member rates.
  
  * Cancer Research publishes about 6,300 pages per year of timely and significant research in the broad subfields of cancer research. With over 69,000 citations to its articles per year, it is the most highly cited journal in the cancer field and is 16th among 4,500 top journals in all scientific fields worldwide.

  * Clinical Cancer Research, our monthly clinical journal, already has more than 4,500 subscribers, and encompasses high-quality clinical and translational cancer research. In addition to preclinical research that bears on human disease, it publishes clinical trials evaluating new treatments for cancer preclinical studies that lead to clinical trials.

  * Cell Growth & Differentiation, the Association's journal covering the molecular biology of cancer, is dedicated to bringing cutting-edge molecular cancer research rapidly to print. With more than 1,800 subscribers, this monthly journal has established itself as an important source of significant new data in molecular oncology. In 1997 Dr. Joseph R. Nevins became the new Editor-in-Chief of this journal.

  * Cancer Epidemiology, Biomarkers & Prevention, features new findings in cancer epidemiology, risk assessment and carcinogenesis, cancer prevention and control, and biomarkers for cancer detection. In 1997 Dr. Frederick P. Li became the new Editor-in-Chief of this monthly publication.

- the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting; (The AACR annual meeting is attended by more than 6,500 scientists from around the world and is the meeting you can’t afford to miss. Scientists consider our annual meeting the most important multidisciplinary cancer meeting which encompasses basic research, clinical cancer research, and the exciting interface area of translational research.)

- an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;

- reduced registration rates at annual meetings;

- priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;

- substantially reduced registration rates for Special Conferences;

- opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;

- receipt of AACR Newsletters and other important announcements;

- early notification of and reduced rates for participation in the AACR Employment Register;

- an up-to-date Directory of Members containing names and addresses of over 13,500 member researchers in the cancer field;

- the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;

- the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;

- the facilitation of informal scientific exchange with leading researchers in the cancer field; and

- many more fringe benefits and services for members.
AACR-HBCU Faculty Award in Cancer Research

Supported by a generous grant provided by the Comprehensive Minority Biomedical Program of the National Cancer Institute

The American Association for Cancer Research (AACR) is extremely pleased to announce the availability of Awards in Cancer Research for full-time faculty members of Historically Black Colleges and Universities (HBCU’s). Supported by a generous grant provided by the Comprehensive Minority Biomedical Program of the National Cancer Institute, AACR-HBCU Faculty Awards in Cancer Research will be presented annually by the American Association for Cancer Research to 20 scientists at the level of Assistant Professor or above engaged in meritorious basic, clinical, or translational cancer research at a non-government, not-for-profit research facility.

The purpose of this Award program is to increase the scientific knowledge base of faculty members at Historically Black Colleges and Universities, and to encourage them and their students to pursue careers in cancer research. Awardees will receive financial support for their participation in the 89th AACR Annual Meeting, March 28-April 1, 1998, in New Orleans, LA. The 1998 AACR Annual Meeting will attract approximately 7,500 scientists from around the world; will provide the latest findings in the most rapidly developing areas of basic, clinical, and translational cancer research; and will feature major presentations from prominent scientists who are making important advances in the field.

The American Association for Cancer Research, a scientific society of more than 13,500 researchers working in all subfields of basic, clinical and translational cancer research, is extremely pleased to sponsor this faculty award.

For Further Information

If after reading the enclosed information you have any questions concerning the application process or Award criteria, or if you have not received the Official Application Form, contact: HBCU Award Coordinator, American Association for Cancer Research, Telephone: (215) 440-9300, FAX: (215) 440-9412, E-mail: felder@aacr.org.
Hormone Receptor Antibodies from Novocastra

- Anti-Estrogen Receptor clone 6F11 (NCL-ER-6F11)
- Anti-Progesterone Receptor clone 1A6 (NCL-PGR)

These mouse monoclonal antibodies are highly effective on formalin-fixed, paraffin-embedded tissues and frozen sections using immunohistochemical techniques. Both NCL-ER-6F11 and NCL-PGR provide specific, reliable and reproducible results. Optimal reactivity on paraffin sections is achieved using a high temperature antigen unmasking technique. Each antibody is available separately or in a 100 test kit form.

ER/PGR Comprehensive Immunohistochemical Kits

<table>
<thead>
<tr>
<th>Kit Description</th>
<th>Kit Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen Receptor Kit</td>
<td>(NCL-ER-Paraffin)</td>
</tr>
<tr>
<td>Progesterone Receptor Kit</td>
<td>(NCL-PGR-Paraffin)</td>
</tr>
<tr>
<td>Estrogen/Progesterone Receptor Kit</td>
<td>(NCL-ER/PGR-Paraffin)</td>
</tr>
</tbody>
</table>

Kit contents include:

- Blocking reagent
- Primary antibody
- Secondary antibody
- Avidin/Biotinylated HRP reagents
- Hydrogen peroxide solution
- DAB tablets
- Stained reference slides
- Unstained control sections
- Relevant journal references
- Full procedural instructions

Please contact our Technical Service Department for further information on antibody and kit specifications or to receive a complete Novocastra Laboratories 1997 catalog, featuring over 350 monoclonal and polyclonal antibodies. These products are for research use only.
Chair

Breast Cancer Research

Vancouver, BC

An endowed Chair in Breast Cancer Research has been created to bring international profile and leadership to a multi-faceted program in breast cancer/breast disease research through a partnership of the Faculty of Medicine, University of British Columbia (UBC), the British Columbia Cancer Agency (BCCA), the Canadian Breast Cancer Foundation, B.C. and Yukon Division (CBCF), and the Robertson family.

The BCCA is an affiliate of UBC and co-hosts the development and conduct of academic oncology in British Columbia.

The BCCA operates a comprehensive cancer control program in the Province of B.C. through four regional cancer centres and a networked communities oncology program. Approximately two-thirds of all patients with cancer in B.C. register for care through the BCCA. In 1996 approximately 2,500 new patients with breast cancer were treated according to the management policies of the Provincial Breast Tumour Group and 172,000 women underwent screening mammography within the Provincial Screening Mammography Program. The B.C. Cancer Research Centre, the largest free-standing cancer research centre in Canada, has a staff of 40 senior scientists, 39 post-doctoral fellows and 47 graduate students. The Centre hosts research divisions that include cancer endocrinology, cancer epidemiology, advanced therapeutics, medical biophysics, cancer imaging and experimental hematopoiesis (Terry Fox Laboratory).

The position entails teaching and active participation within the individual's home department and leadership of a personal research initiative, as well as responsibility for the overall direction and coordination of activities in breast cancer-related research at BCCA, UBC and UBC-affiliated institutions.

Applications are invited from individuals who have experience in research applicable to breast cancer and hold Ph.D. and/or M.D. qualifications. In addition, they should be eligible for appointment at Associate or Full Professor rank with tenure (grant) at UBC and, if medically-qualified and wishing to practice clinical medicine, hold or be eligible for Canadian specialist qualifications in the appropriate discipline and be eligible for licensure to practice medicine in B.C. Key attributes of the successful applicant will include innovation; collaborative relationships with local, national and international research peers; and the ability to build a strategically-focused multidisciplinary program of excellence in breast cancer research.

In accordance with Canadian Employment and Immigration requirements, preference will be given to Canadian citizens and permanent residents of Canada. UBC hires on the basis of merit and is committed to employment equity. We encourage all qualified persons to apply.

Letters of application should be submitted with a current curriculum vitae to: Dr. S.B. Sutcliffe, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6; telephone (604) 877-6104; fax: (604) 872-4596. Closing date: Feb. 28, 1998.
Chairperson, Developmental Therapeutics Department, Medicine Branch, Division of Clinical Sciences, National Cancer Institute

The Division of Clinical Sciences, NCI invites applications for the position of Chair of the newly formed Developmental Therapeutics Department within the Medicine Branch. This is the largest of the four departments in the restructured Medicine Branch and encompasses principal investigators focused on the development of novel therapeutics in medical oncology. Candidates should have an M.D. or M.D./Ph.D. degree and should be recognized for research excellence in molecular pharmacology, biochemistry, or DNA repair. The successful candidate will provide scientific direction for the department and will establish translational programs taking advantage of the resources available at the NIH to advance new therapeutic modalities.

U.S. citizenship or resident alien status is required. Applicants should send a curriculum vitae and bibliography, up to three reprints, a statement of the candidate's research program, and five letters of recommendation by January 31, 1998 to:

Douglas Lowy, M.D.
Deputy Director, Division of Basic Sciences
National Cancer Institute
31 Center Dr. MSC 2440
Building 31, Room 3A-11
Bethesda, MD 20892-2440

NIH IS AN EQUAL OPPORTUNITY EMPLOYER.

CALL FOR ABSTRACTS

Fifth Research Workshop on the Biology, Prevention and Treatment of Head and Neck Cancer
August 26–30, 1998
McLean Hilton at Tysons Corner
McLean, Virginia

Abstract Deadline: March 17, 1998

For information and abstract form, telephone, fax or e-mail:
Talley Management Group
19 Mantua Road
Mt. Royal, NJ 08061
Tel: (609) 423-3195  Fax: (609) 423-3420
e-mail: meetings@smarthub.com

This Workshop is presented by the American Society for Head and Neck Surgery and the Society of Head and Neck Surgeons and is intended to be a multi-disciplinary international research forum stressing new research developments in all fields related to head and neck cancer. Participation from international researchers in both basic and clinical sciences is encouraged.

Conference Coordinators:
Stimson P. Schantz, MD,
New York, New York, and
Bettie M. Steinberg, PhD,
New Hyde Park, New York

FACULTY POSITION
UNIVERSITY OF PITTSBURGH CANCER INSTITUTE

The University of Pittsburgh Cancer Institute (UPCI) is seeking an ASSISTANT or ASSOCIATE PROFESSOR to join the LUNG CANCER CENTER BASIC SCIENCE PROGRAM. The successful candidate will become a member of the UPCI and receive a tenure-track position in an appropriate department in the University of Pittsburgh School of Medicine. The candidate will be expected to establish an externally funded research program and to help develop a translational research program in lung cancer in collaboration with other members of the UPCI Lung Cancer Center. The position is available immediately and will remain open until filled. Research areas of particular interest are lung cancer genetics, biomarkers, and early detection of lung cancer.

Applicants should have a Ph.D. and/or M.D. degree and postdoctoral training. Send curriculum vitae, summary of research interests, and names of three references to:
Jill M. Siegfried, Ph.D.
Director, UPCI Lung Cancer Center Basic Science Program
Department of Pharmacology
University of Pittsburgh School of Medicine
E1340 Biomedical Science Tower, 3500 Terrace Street
Pittsburgh, PA 15261

The University of Pittsburgh is an Equal Opportunity/Affirmative Action Employer
The Developmental Therapeutics Department of the Medicine Branch is recruiting for a Tenure-Track position within the Division of Clinical Sciences, National Cancer Institute, National Institutes of Health.

Applicants need to have an M.D. and/or Ph.D. and be U.S. citizens or permanent residents. Preference will be given to candidates who are board certified or eligible in Medical Oncology. The qualified applicant should be interested in developing an independent research program on the morphological, genetic, and/or biochemical characterization of smoking-related malignancies and their precursor lesions. Candidates will be expected to participate in translational programs studying patients at risk for development smoking-related cancers (especially lung cancer). Successful candidates should have experience in addressing disease oriented questions using molecular genetic and/or cellular pharmacology approaches. Space, technical support, and salary are committed.

The application should include a cover letter, curriculum vitae, bibliography, a one-two page statement of research interests and goals, and selected publication (3-5) to the address listed above. Please arrange to have letters of recommendation sent from 3 references who can provide an evaluation of your professional qualifications.

The completed applications should be postmarked by February 10, 1998 to:

James Mitchell, Branch Chief (Chairperson)  
Radiation Biology Section  
Bldg. 10, B3B69  
8900 Wisconsin Avenue  
Bethesda, MD 20892-1002  
(301) 496-7511 (phone)  
(301) 480-2238 (facsimile)  
NIH IS AN EQUAL OPPORTUNITY EMPLOYER

---

**Academic Position for a Research-Oriented Medical Oncologist**

The USC/Norris Comprehensive Cancer Center at the University of Southern California School of Medicine has created a new tenure track faculty position for a research-oriented medical oncologist to take a leadership role in an interdisciplinary, translational research program, centered around the molecular biology/genetics/therapeutics of breast cancer. The research program will take advantage of well-established clinical NIH-funded research programs of the campus including the USC/Norris Breast Center with its rich racial-ethnic diversity of Los Angeles County.

Candidates will be considered for appropriate faculty rank in the Division of Medical Oncology of the Department of Medicine with salary commensurate to rank and experience. New state-of-the-art research facilities and generous start-up research support are available for the successful candidate. Laboratory or clinical research experience is required. USC is an equal opportunity employer. Interested candidates should send a curriculum vitae and names of three references to the following address by March 1, 1998:

Michael F. Press, M.D., Ph.D.  
Breast Cancer Research Program  
USC/Norris Comprehensive Cancer Center  
1441 Eastlake Avenue, Room 5410  
Los Angeles, CA 90033  
Phone: (213) 764-0563  
Fax: (213) 764-0122

---

The Rush Cancer Institute is seeking to recruit a senior physician to establish and run a Phase I/II program in chemotherapeutic agents. The Institute and its Affiliates constitute 8 Hospitals which together see over 6,000 new cancer patients each year. The position being offered is tenured and applicants should have at least 5 years experience in this area. Laboratory and personnel support will be provided to the individual chosen for this position. Applications and inquiries should be sent to Rush-Presbyterian-St. Luke’s Medical Center,

Dr. Donald Braun  
Scientific Program Director  
The Rush Cancer Institute  
1653 W. Congress Parkway  
Chicago, Illinois 60612  
telephone #312-563-2190 or fax #312-455-9635.
At Abbott Laboratories, our mission is clear: to improve lives. We've introduced some of the most impressive innovations in health care, and continue to provide quality health care products far into the future. With 54,000 employees worldwide and more than $11 billion in annual sales, our achievements are recognized globally. We seek the following professional to join our suburban Chicagoland corporate headquarters.

In this highly important role, you will develop tumor models in laboratory rodents, evaluate novel experimental and standard drugs and manage laboratory staff. Tumor systems utilized include solid flank, orthotopic, systemic and metastatic systems. The candidate drugs are often novel non-cytotoxic compounds.

The qualified candidate will possess a Ph.D. in tumor biology or DVM with oncology experience. The ability to conduct pharmacodynamic evaluations of preclinical candidate compounds and rapidly learn and contribute to new areas is important. Tissue culture skills and familiarity with toxicology and pharmacokinetics is required. Written and oral communication skills and the ability to collaborate with others in diverse areas are necessary. Some travel is involved.

At Abbott Laboratories, your contribution will be vital to our mission of improving lives. In return for your expertise, we offer a competitive compensation package, including full benefits. For consideration, please send your resume with salary history to: Job Code 97-LAM-4110, Dept. 0583, Bldg. AP9A, Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, IL 60064. An EOE, we are as committed to employee diversity as we are to our broad range of products and services.

www.abbott.com

Hit our Home Page on the World Wide Web!

http://www.aacr.org

Our web site features:

AACR scientific meeting schedule

Table of Contents of AACR journals

Instructions for Authors

Information about AACR Research Fellowships and Travel Awards

Plus . . . The latest AACR newsletter, and much more!
Clinical Cancer Research

SPECIAL ISSUE:
Foundations of Clinical Cancer Research – Perspective for the 21st Century

Featuring peer-reviewed papers by leading clinical researchers in the areas of:
- Scientific Basis of Clinical Trials
- Developmental Therapeutics
- Combined Modality Therapy
- Supportive Care
- Exploitable Molecular Mechanisms

Also, published for the first time:
Dr. Emil J Frei's influential 1976 David A. Karnofsky Lecture on clinical research.

To order, call the American Association for Cancer Research (AACR) at 215/440-9300; fax to 215/440-9355; e-mail to pubs@aacr.org; or fill out and return the order form below.

ORDER YOUR COPY OF THIS SPECIAL ISSUE TODAY

[Form for ordering the special issue]

Send me the special issue of Clinical Cancer Research, "Foundations of Clinical Cancer Research".

☐ Check enclosed* (Payable to AACR)
☐ Charge my:
  ☐ MasterCard ☐ VISA ☐ American Express

Account Name

Account Number Exp. Date

Signature

*Check must be in U.S. dollars drawn on a U.S. bank.

Name

Title

Address

City State/Province Postal Code Country

Mail form to: American Association for Cancer Research, 150 S. Independence Mall West, Suite 826, Philadelphia, PA 19106-3483.

Those paying by credit card can fax form to the AACR at 215/440-9355.

Clinical Cancer Research is an Official Journal of the American Association for Cancer Research.
E. Richard Stanley's (cover) research career has focused on the identification, characterization, and mechanism of action of colony stimulating factor-1 (CSF-1), also known as macrophage colony-stimulating factor (M-CSF), that controls the survival, proliferation, and differentiation of mononuclear phagocytes and regulates the cells of the female reproductive tract. His early training was in Australia, where he was awarded a first-class honors degree in Biochemistry from the University of Western Australia in 1967 and his Ph.D. from the University of Melbourne in 1970. As a graduate student in the laboratory of Donald Metcalf at the Walter and Eliza Hall Institute, Dr. Stanley initiated the work in that laboratory on the biochemical characterization of the colony stimulating factors in collaboration with T. R. Bradley of the Physiology Department at the University of Melbourne. Dr. Stanley remained in Dr. Metcalf's laboratory as a postdoctoral fellow prior to moving, in 1972, to the Ontario Cancer Institute as a lecturer, then Assistant Professor, in the Department of Medical Biophysics at the University of Toronto. In 1977, he moved to the Albert Einstein College of Medicine as Assistant Professor of Microbiology and Immunology, rising through the ranks to Professor in 1984. Since 1987, he has been the Renée and Robert A. Belfer Professor of Developmental Biology and Chair of the Department of Developmental and Molecular Biology at Einstein, and he is the leader of the Program in Receptor Mediated Growth and Differentiation at the Albert Einstein Cancer Center. In these capacities, he has been involved in establishing shared interdepartmental facilities, including a large protein chemistry facility, and in fostering interdepartmental collaborations in developmental biology and signal transduction.

In his own laboratory, Dr. Stanley has focused on the biology of CSF-1 and its regulation of normal and neoplastic cells. His laboratory was the first to purify a colony stimulating factor, CSF-1. They then developed radioimmuno- and radioreceptor assays for both mouse and human CSF-1, delineating CSF-1 as a subclass of the CSFs. He and his collaborators reported the cloning of human CSF-1 in 1985. Prior to this, and following a detailed analysis of the interaction of 125I-CSF-1 with its receptor on macrophages, Dr. Stanley's laboratory purified the CSF-1 receptor and demonstrated its intrinsic tyrosine kinase activity. Shortly afterwards, in 1985, in collaboration with the group of C. J. Sherr, Dr. Stanley's laboratory showed that the CSF-1 receptor is encoded by the c-fms proto-oncogene product. In 1986, they described the synergistic action of CSF-1 with hemopoietin-1 on very primitive hematopoietic cells. Hemopoietin-1, the purification of which they described in 1985, during a collaboration with Dr. Bradley, was subsequently shown by others to be interleukin-1α, following the expression-cloning of the interleukin-1α cDNA. In 1986 and 1987, papers from Dr. Stanley's laboratory describing the expression of CSF-1 and its regulation in the female reproductive tract introduced a new area of research into CSF-1 action that had significant repercussions for studies of its role in neoplasia. In subsequent collaborations with H. S. Gilbert, A. Janowska-Wieczorek, B. M. Kacinski, and S. M. Scholl, circulating CSF-1 was shown to be elevated in patients with myeloproliferative disease, leukemia, and tumors of the female reproductive system, and expression of CSF-1 and its receptor in some neoplasias was shown to be consistent with an autocrine or paracrine role for the growth factor. In 1990, Dr. Stanley's laboratory, in collaboration with Wieslaw Wiktór-Jedrzejczak, reported, simultaneously with H. Yoshida and colleagues, that the basis of the osteopetrotic mutation in the mouse was a lack of active CSF-1. Subsequent studies on this mouse, carried out in collaboration with J. W. Pollard's laboratory at Einstein and others, significantly increased our understanding of the biology of CSF-1. Osteopetrotic (op/op) mice not only have decreased numbers of osteoclasts and tissue macrophages, but also male and female fertility problems and visual and auditory processing defects that lead to blindness and deafness. Studies of Dr. Stanley and his collaborators indicate that many of these problems may be associated with a lack of macrophages that have trophic and scavenger roles important for the function and/or development of the tissues in which they reside.

In their studies on CSF-1 signal transduction, Dr. Stanley's laboratory has focused on the very early events that take place in macrophages following occupation of the receptor by CSF-1. They identified early changes in the receptor, including its dimerization and subsequent modifications and developed methods for purification and sequencing of proteins that are rapidly tyrosine phosphorylated in response to growth factor and for the proteins that are associated with them. These studies have led to the cloning of genes encoding novel proteins as well as to in-depth investigations of the role of protein tyrosine phosphatases (SHP-1, PTP-phi) and a proto-oncogene product (Cbl) in CSF-1 signal transduction.

Recently, Dr. Stanley's laboratory isolated a Drosophila cDNA encoding a novel class of cytoplasmic tyrosine kinase. This SH2 domain-containing, ankyrin repeat kinase was termed Shark. Shark is expressed in ectodermal epithelium and in epithelial structures derived from it. In collaboration with David Stein of Einstein, and in addition to the work on CSF-1, Dr. Stanley's laboratory has initiated a program to determine the role of this kinase in Drosophila. Shark is conserved between cnidarians and humans and is essential in Drosophila.

Dr. Stanley has served on the editorial boards of 11 journals including Blood, the Journal of Experimental Medicine, and the Journal of Biological Chemistry. He has served on the advisory board of the International Council for Coordinating Cancer Research and consulted for several biotechnology companies. He has received several honors including a Leukemia Society of America Scholar Award (1977—82), an Irma T. Hirschl Career Scientist Award (1983—87), and a Lucille P. Markey Charitable Trust Award (1988—94). In 1989, he received an NIH Merit Award and the Research Award of the Society of Leukocyte Biology. He has organized several international and national scientific meetings and currently serves on the Hematology-1 Study Section of the NIH. He is also a member of several professional scientific organizations, including the American Association for Cancer Research.

His wife, Pamela Stanley, is Professor of Cell Biology at Albert Einstein College of Medicine and is internationally known for her work in glycobiology. They have 2 sons, Damian, 22 years, and Robert, 14 years.

Sidney Weinhouse